Home › Learn › PSA and prostate cancer
Active Surveillance for Prostate Cancer
Active surveillance means carefully monitoring a selected prostate cancer instead of treating it right away. It is generally the preferred first approach for well-characterized low-risk prostate cancer, and some men with favorable intermediate-risk disease may also be candidates. It is not doing nothing. It is a disciplined schedule of PSA tests, imaging and repeat biopsies, with treatment started if the cancer shows signs of changing. The aim is to avoid treatment that may never have been needed, and to protect urinary and sexual function, while still watching closely.
Many men find this hard to accept. They hear the word cancer and assume treatment must begin immediately. But with prostate cancer, the biology matters more than the word.
Why watching can be the smart choice
Prostate cancer is not one disease. Some prostate cancers grow slowly, may never spread and may never need treatment in a man's lifetime, especially if he is older or has other health problems. Others are aggressive and need timely treatment.
Treating every low-risk cancer immediately can expose men to the side effects of surgery or radiation, such as urinary leakage, erection problems and loss of ejaculation, without improving their lives. Active surveillance exists to avoid harming a man by overtreating a cancer that may never hurt him. If the cancer stays quiet, he avoids or delays treatment. If it changes, treatment can start while it can still be aimed at cure.
Who is a candidate
The most common candidate has Grade Group 1 cancer, also called Gleason 6 or 3+3. The name confuses many men, because 6 sounds like more than half of 10. In fact, Gleason 6 is generally the lowest grade of prostate cancer commonly reported on biopsy, and many of these cancers behave in a very low-risk way.
Some men with favorable intermediate-risk cancer can also be considered. This usually means a small amount of Gleason 3+4 (Grade Group 2) with other reassuring features, such as low-volume disease, limited pattern 4, low PSA density and reassuring imaging. That decision needs careful counseling. Not every intermediate-risk cancer should be watched.
Certain findings make surveillance less appropriate or move the conversation toward treatment:
- Gleason 4+3 (Grade Group 3). Both 3+4 and 4+3 add up to 7, but they are not the same disease. In 4+3 the more aggressive pattern dominates.
- More extensive cancer. Cancer in many biopsy samples, or a large amount in each, is different from one tiny focus.
- Cribriform or intraductal features. These microscopic patterns can be linked to more aggressive behavior.
- Imaging that does not match. If the MRI showed a large suspicious lesion but the biopsy found only a little low-grade cancer, the team should make sure that area was adequately sampled.
What monitoring involves
Surveillance is structured observation. The exact schedule is set by your care team, but it typically combines:
- Regular PSA testing to follow the trend.
- Prostate MRI when appropriate, to reassess suspicious areas and guide later sampling.
- Repeat biopsy when needed, to confirm the cancer has not become more aggressive.
- Clinical judgment that brings all of these together at each review.
MRI adds information to a surveillance plan, but it does not replace all repeat biopsies or other requirements. When the decision between surveillance and treatment is close, genomic testing of the biopsy tissue can sometimes help. These tests look at gene activity in the tumor to estimate how quietly or aggressively it may behave. They support clinical judgment rather than replace it.
Surveillance requires discipline from both sides. The man has to keep his appointments, and the team has to take any change in risk seriously. Before you start, you should know the schedule of tests and the specific findings that would trigger a treatment discussion.
Active surveillance is not watchful waiting
These two terms are often confused, but their goals are different. Active surveillance is a structured plan for men who could still be cured by treatment if the cancer changes. The goal is to monitor closely and intervene if needed.
Watchful waiting is usually less intensive. It is often used for men who are older, frailer or unlikely to benefit from curative treatment, and the aim may be to avoid treatment unless symptoms develop. A healthy 60-year-old on active surveillance is in a very different situation from an 89-year-old with serious medical conditions who is being watched conservatively. Ask which strategy is being recommended for you, and why.
Things to discuss while on surveillance
Urinary symptoms. Many men with prostate cancer also have an enlarged prostate. The cancer and the benign obstruction are often two separate problems in the same organ. If you have a weak stream or are leaving urine behind, that may need its own evaluation and treatment plan. A BPH treatment does not treat cancer, and a cancer plan does not automatically relieve obstruction.
Testosterone. Testosterone therapy during active surveillance is uncertain territory because the cancer has not been treated. The Endocrine Society recommends against testosterone therapy in men with prostate cancer. If low testosterone symptoms are a problem, talk with the clinician managing your cancer about the evidence and alternatives before starting anything.
Your peace of mind. Some men find living with an untreated cancer too stressful. That is a legitimate feeling and worth discussing honestly. The goal is an informed choice, not pressure in either direction.
When surveillance turns into treatment
If repeat testing shows a higher grade, more cancer or concerning imaging, the plan changes. Moving from surveillance to treatment is not a failure. It is the system working as designed: the cancer was watched closely, and treatment began when it was needed. Our guide to prostate cancer treatment options explains what comes next.
Questions to ask before choosing surveillance: What is my Grade Group, and how much cancer was found? Was the MRI lesion sampled? Are there cribriform or intraductal features? Would genomic testing help? What is my testing schedule, and what would make you recommend treatment? If you are weighing this choice, talk to a urologist and consider a second opinion when the decision is close.
Find a urologist near you
Search by state, county or ZIP code, see who accepts Medicare, and read moderated patient reviews.
Already seen a urologist? Find them in your state and rate your visit: it takes a minute, and your name is not shown.
Frequently asked questions
- Is active surveillance the same as doing nothing?
- No. It is a structured plan of PSA tests, MRI when appropriate and repeat biopsies when needed, with treatment started if the cancer shows signs of becoming more aggressive.
- Who is a good candidate for active surveillance?
- Most often men with low-risk Grade Group 1 (Gleason 6) cancer. Some men with favorable intermediate-risk disease, such as a small amount of Gleason 3+4 with reassuring features, may also qualify after careful counseling.
- What is the difference between active surveillance and watchful waiting?
- Active surveillance closely monitors men who could still be cured if the cancer changes. Watchful waiting is usually less intensive and often used for older or frailer men, with treatment reserved for symptoms.
- Can I take testosterone while on active surveillance?
- This is uncertain. The Endocrine Society recommends against testosterone therapy in men with prostate cancer, so any discussion should happen with the clinician managing your cancer.